Business Context and Reporting Period
This Form 8-K was filed by Aquestive Therapeutics, Inc. on February 25, 2021. The report addresses Item 8.01 (Other Events) regarding a press release issued on the same date. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a corporate event rather than financial performance data.
Material Changes
The material event reported is the reaffirmation of the Company's plan to resubmit its New Drug Application (NDA) for its drug candidate, Libervant, around the end of the second quarter of 2021.
Guidance, Outlook, and Management Commentary
Management has provided a specific timeline for regulatory activity, targeting the end of Q2 2021 for the resubmission of the Libervant NDA. No other guidance, risks, or contingencies are detailed within the body of this specific 8-K filing.
Investor Verification Checklist
- Verify the status of the Libervant New Drug Application resubmission by the end of Q2 2021.
- Review the attached press release (Exhibit 99.1) for detailed rationale regarding the resubmission timeline.
- Confirm the Company's cash runway and funding status in subsequent filings, as this 8-K contains no liquidity data.